Skip to main content

Table 2 Summary of ceftolozane and tazobactam steady-state pulmonary ELF exposures in patients with HABP/VABP

From: Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Exposure measure Statistic Ceftolozane Tazobactam
CrCl ≥ 80 to < 150 mL/min CrCL ≥ 150 to < 180 mL/min CrCL ≥ 180 to < 210 mL/min CrCL ≥ 210 mL/min CrCl ≥ 80 to < 150 mL/min CrCL ≥ 150 to < 180 mL/min CrCL ≥ 180 to < 210 mL/min CrCL ≥ 210 mL/min
AUC0–8 (μg × h/mL) n 138 24 16 20 138 24 16 20
Geometric mean (geometric %CV) 199 (78.9) 149 (64.0) 127 (86.6) 118 (69.6) 24.7 (108) 14.4 (72.1) 16.0 (85.9) 13.6 (77.5)
Cmax (μg/mL) n 138 24 16 20 138 24 16 20
Geometric mean (geometric %CV) 28.3 (78.8) 21.0 (69.8) 17.4 (87.8) 15.9 (71.7) 4.68 (107) 2.78 (65.7) 3.31 (92.9) 2.81 (85.6)
  1. Among all participants from the intention-to-treat population who had pharmacokinetic data collected
  2. AUC0–8, area under the concentration–time curve from time 0 to 8 h after start of infusion; Cmax, maximum drug concentration; CrCl, creatinine clearance; CV, coefficient of variation; ELF, epithelial lining fluid; HABP/VABP, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia